MILESTONE SCIENTIFIC INC. MLSS Cash Flow

Milestone scientific inc. (MLSS)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Net (loss) income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from operating activities:
Net loss
-8,399	-7,580	-4,658	-6,212	-6,509	-7,691	-9,563	-6,576	-6,766	-5,369	-5,508	-6,058	-6,611	-7,294	-6,740	-6,348	-6,373	-5,539	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,464	77	-125	-364	-870	-909	-1,562	-1,695	-1,482	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
58	47	50	50	51	66	72	72	73	62	67	77	86	92	76	60	44	27	26	24	19	17	17	16	17	18	17	17	17	18	20	21	22	22	0	0	0
Amortization of patents
53	53	53	371	590	814	1,124	944	730	510	204	70	70	70	70	70	69	69	71	73	76	78	78	78	78	77	77	77	76	76	75	78	80	83	0	0	0
Stock compensation
157	183	308	339	379	409	367	584	621	651	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Employee bonus paid in stock
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	4	6	6	5	0	0	0
Common stock and options for compensation, consulting and vendor services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,520	1,490	1,128	1,206	1,234	1,025	1,031	888	882	884	1,077	904	853	912	673	440	913	833	864	0	0	0
Accrued interest expense on notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0	-	-	-	-
Bad debt reversal
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-362	-369	-221	-207	-142	-128	-116	-86	0	0	0
Loss (Income) from earnings on China joint venture
-	81	120	263	302	329	0	0	-83	-	-	-602	-526	-795	-1,240	-1,620	-2,357	-2,445	0	0	0	-	-	-	-	-	-	-	-	-171	0	0	0	-	-	-	-
Change in fair value of derivative liability
-	-3,635	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash operating lease expense
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Decrease in accounts receivable
-223	-267	225	-181	678	442	-985	420	-792	733	-197	-17	-286	-635	158	113	581	207	725	191	421	8	-91	313	-431	126	381	-596	-120	-525	-483	-782	-469	172	0	0	0
Decrease in accounts receivable, related party
-	-100	558	-1,000	142	192	546	2,461	411	-989	-274	-1,787	326	1,727	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in other receivables
6	9	0	0	0	-	-	-	-	-	-	-	-	-48	-85	67	-210	58	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Increase) decrease in inventories
-138	-300	-813	-788	-860	-914	-971	-1,677	-1,048	-1,003	-153	171	800	509	793	365	984	875	563	1,276	283	1,175	1,366	1,107	1,119	683	203	342	36	-151	-63	-83	-261	-196	0	0	0
(Increase) decrease in advances on contracts
245	61	-256	-331	-454	-48	-107	10	122	-3	-276	-363	-391	-514	13	448	252	450	-99	-950	-1,024	-1,587	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Decrease to advances on contracts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Decrease to advance to contracts
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-140	342	962	0	0	0
Increase in prepaid expenses and other current assets
88	104	58	-78	101	-21	-105	-261	-4	144	275	370	-5	-12	0	0	0	-	-	-	-	304	163	10	35	-88	-33	-136	-131	-65	-129	-57	-20	-17	0	0	0
(Decrease) increase in accounts payable
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in other assets
-	-	-	-	-	-	-	-	0	9	9	15	9	0	0	-11	-227	-2	0	0	0	-	-	-	-	-	-	-	-	-20	-48	-32	-38	-47	0	0	0
(Decrease) increase in accounts payable
-	-	-	-	-	-	-	503	667	-363	-408	-141	272	486	0	0	0	-	-	-	-	-516	-415	-471	-813	-316	-798	-1,579	-1,376	-1,594	-976	-672	-189	607	0	0	0
(Decrease) increase in accounts payable, related party
-9	-303	100	54	325	678	550	847	-7	-249	-332	-173	-152	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in deferred cost, related party
-	-50	-329	-545	165	191	1,217	1,614	928	489	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accrued expenses
346	273	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	124	-67	-116	-26	-25	-57	173	59	-249	123	111	0	0	0
(Decrease) increase in accrued expenses, related party
1,042	1,228	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Decrease) in deferred revenue, related party
-	-100	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in customer advances
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
(Decrease) increase in accrued expenses and other payables
-	-	-	-	-	-	-	-	1,718	-	-	319	-473	-755	31	-9	388	220	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Decrease in deferred revenue, related party
-	-	-	-	-	-	-	-	1,369	-	712	356	356	1,001	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment in Joint Venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Net cash used in operating activities
-2,530	-1,779	-946	-733	-1,306	-1,628	-1,626	-1,793	-896	-1,229	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	339	67	-10	-49	-216	-154	-211	-570	0	0	0
Cash flows from investing activities:
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,558	-3,654	-2,946	-3,382	-2,204	-581	376	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Notes receivable from Milestone Medical
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Due from related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of intangible assets
-	-	-	-	-	-	-	-	-	-	-	-	-	15	0	0	0	-	-	-	-	-	-	-	-	21	22	30	25	26	25	22	29	31	0	0	0
Investment in Medical joint venture
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
8	9	0	0	0	-	-	-	7	6	5	3	10	15	34	40	69	67	63	103	80	82	68	23	9	5	0	0	0	-	-	-	-	7	0	0	0
Net cash used in investing activities
-8	-9	-10	-18	-22	-15	-15	-161	-200	-199	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-335	-132	-81	-31	-30	-26	-34	-39	0	0	0
Cash flows from financing activities:
Proceeds from exercise of warrants
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments of finance leases
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Consolidation of variable interest entity
-	-	-	-	-	-	-	-	-	-	-	-	-	39	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from Public Placement Offering
-	1,974	0	0	0	-	-	-	0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	200	50	50	50	150	0	0	0	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,291	-3,405	-3,727	-3,567	1,372	-1,696	-1,304	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Capital contribution from noncontrolling interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	0	62	0	0	0	-	0	0	0	-	-	-	-	348	0	0	0	-	-	-	-	-	-	-	-	25	0	0	0
Net proceeds from Private Placement Offering
-	250	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from related party loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,003	400	500	1,058	1,158	10,210	10,148	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net decrease in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,736	-6,659	-6,173	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
566	2,562	2,253	2,224	1,974	-250	-250	-125	250	463	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	124	114	100	150	150	204	204	79	0	0	0
Net increase (decrease) in cash and cash equivalents
-2,013	772	1,296	1,471	685	-1,893	-1,892	-2,079	-847	-965	0	0	0	-	-	-	-	-	-	-	-	-	-	950	1,277	981	128	49	8	68	-97	23	-42	-530	0	0	0
Supplemental non-cash disclosure of cash flow information:
Shares issued to employee for bonuses
-	-	-	-	-	-	-17	399	339	194	259	244	584	389	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued to board of directors
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued to board of directors for services rendered
-	67	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued to employees for compensation
213	37	0	0	0	-	-	-	306	350	422	713	410	366	0	0	0	-	-	-	-	-	47	47	47	47	47	47	47	43	0	0	0	-	-	-	-
Shares issued to consultants in lieu of cash payments
425	440	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net assets acquired from variable entity
-	-	-	-	-	-	-	-	-	-	-	-	-	16	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Initial recognition of operating lease-right of use assets
373	-166	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Initial recognition of operating lease right to used liabilities
-373	166	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease right to used liability
-373	166	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Derivative liability
-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense paid in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23	0	0	0
Net proceeds on Private Placement Offering
-	250	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares to be issued to directors for prepaid directors' fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-